Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Gyre — Other Nonoperating Income Expense

Other segment segments

Gyre Pharmaceuticals
-$391K+22.9%

Similar metrics at other companies

BioSig Technologies, Inc. logo
STEXCorporate — Other Nonoperating Income Expense
$73K+587%
KRAKacquisition logo
KRAQSingle — Other Nonoperating Income Expense
$0
Vivid Seats Inc. logo
SEATConsolidated — Other Nonoperating Income Expense
-$1.07M-126%
SEG
SEGHospitality — Other Nonoperating Income Expense
-$150.75K-113%
Warrior Met Coal logo
HCCMining — Other Nonoperating Income Expense
$0
ANN
ANNAConventional — Other Nonoperating Income Expense
$5.15M+815%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemThree Months Ended June 30,Six Months Ended June 30,
(Loss) income from operations(2,240))302)
Other (loss) income, net:
Interest income9411,797
Other expense, net(488))(301))
Change in fair value of warrant liability2122,467
(Loss) Income before income taxes(1,575))4,265)
Benefit (provision) for income taxes(662)(1,563))
Net (loss) income(2,237))2,702)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense?
Gyre Therapeutics, Inc. (GYRE) reported gyre — other nonoperating income expense of -$552K in Q2 2026.
How has Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense changed year-over-year?
Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense decreased by 3005.3% year-over-year, from $19K to -$552K.
What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense?
Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense has grown at a -37.6% compound annual growth rate (CAGR), from -$272K to -$106K.
What does gyre — other nonoperating income expense mean?
This captures financial impacts that fall outside the scope of the segment's primary business operations, such as foreign exchange gains or losses, asset disposals, or miscellaneous income. It provides a view of peripheral financial activities that affect the overall bottom line. Investors analyze this to isolate core operational performance from incidental financial events.

Ask your AI about Gyre Therapeutics, Inc.'s gyre — other nonoperating income expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude